Cargando…

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rios-Doria, Jonathan, Durham, Nicholas, Wetzel, Leslie, Rothstein, Raymond, Chesebrough, Jon, Holoweckyj, Nicholas, Zhao, Wei, Leow, Ching Ching, Hollingsworth, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674486/ https://www.ncbi.nlm.nih.gov/pubmed/26408258 http://dx.doi.org/10.1016/j.neo.2015.08.004

Ejemplares similares

Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil
por: Banciu, Manuela, et al.
Publicado: (2008)

Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016)

Multimodality Imaging of Tumor Response to Doxil
por: Zhang, Fan, et al.
Publicado: (2011)

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells
por: Wu, Xian, et al.
Publicado: (2018)

GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory
por: Durham, Nick M., et al.
Publicado: (2017)

Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil(®)) in C26 Tumor-Bearing Immunocompetent Mice
por: Takayama, Takuma, et al.
Publicado: (2020)

Combination of Autophagy Selective Therapeutics With Doxil: An Assessment of Pathological Toxicity
por: Helke, Kristi L., et al.
Publicado: (2022)

Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro
por: Neun, Barry W., et al.
Publicado: (2018)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance
por: Wei, Xiaohui, et al.
Publicado: (2018)

Optimizing the time of doxil injection to increase the drug retention in transplanted murine mammary tumors
por: You, Shaojin, et al.
Publicado: (2010)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil(Ⓡ)
por: Zhang, Ruoshi, et al.
Publicado: (2020)

Protocol to assess the antitumor efficacy of an immunotherapeutic peptide in syngeneic orthotopic glioma mouse models
por: Chen, Apeng, et al.
Publicado: (2023)

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats
por: ten Hagen, T L M, et al.
Publicado: (2004)

TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
por: Zeng, Zexian, et al.
Publicado: (2021)

Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response
por: Zeng, Zexian, et al.
Publicado: (2022)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi, Reza, et al.
Publicado: (2020)

Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
por: Nordström, Rickard, et al.
Publicado: (2021)

Response of Syngeneic Murine Lymphomata to Immunotherapy in Relation to the Antigencity of the Tumour
por: Parr, Iris
Publicado: (1972)

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model
por: Dobson, Christine C, et al.
Publicado: (2016)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil(®)) to Tumour Cells Using a Novel TIMP3 Peptide
por: Aldughaim, Mohammed S., et al.
Publicado: (2020)

Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
por: Khalsa, Jasneet Kaur, et al.
Publicado: (2021)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM
por: Liu, Ching-Ann, et al.
Publicado: (2022)

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
por: Harper, James, et al.
Publicado: (2021)

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
por: Georgiev, Peter, et al.
Publicado: (2022)

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity
por: Schuelke, Matthew R., et al.
Publicado: (2019)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

Targeting tumor-associated macrophages to synergize tumor immunotherapy
por: Xiang, Xiaonan, et al.
Publicado: (2021)

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
por: Rajeev-Kumar, Greeshma, et al.
Publicado: (2022)

In Vivo Safety, Biodistribution and Antitumor Effects of uPAR Retargeted Oncolytic Measles Virus in Syngeneic Cancer Models
por: Jing, Yuqi, et al.
Publicado: (2014)

THE CYTOTOXIC EFFECT OF MOUSE MACROPHAGES ON SYNGENEIC AND ALLOGENEIC ERYTHROCYTES
por: Melsom, H., et al.
Publicado: (1973)

Application of immunotherapy based on dendritic cells stimulated by tumor cell-derived exosomes in a syngeneic breast tumor mouse model
por: Piao, Yin Ji, et al.
Publicado: (2021)

Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model
por: Yang, Sung-Yoon, et al.
Publicado: (2023)

Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity
por: de Gruil, Nadia, et al.
Publicado: (2022)

Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro
por: Dadashi Noshahr, Karim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vb225382d2rcqjopvrqtcbah40